Zydus Lifesciences Q1 Results: Profit Up 30%, Beats Estimates
Profits for the company grew 30% to 1,420 crore against the consensus estimate of Rs 1,279 crore per analysts tracked by Bloomberg.
Zydus Lifesciences Ltd.'s consolidated net profit rose 30% in the first quarter of fiscal 2025, surpassing analysts' estimates.
The company posted a net profit of Rs 1,420 crore in the quarter-ended June, in comparison with Rs 1,087 crore in the year-ago period, according to an exchange filing on Friday. Analysts tracked by Bloomberg had estimated a profit of Rs 1,279 crore.
Zydus Lifesciences Q1 FY25 Highlights (Consolidated, YoY)
Revenue up 20.8% at Rs 6,208 crore versus Rs 5,140 crore (Bloomberg Estimate: Rs 5,869.8 crore)
Ebitda up 37.6% at Rs 2,109 crore versus Rs 1,533 crore (Bloomberg Estimate: Rs 1,844.3 crore)
Margin at 34% versus 29.8% (Bloomberg Estimate: 31.4%)
Net profit up 30.6% at Rs 1,420 crore versus Rs 1,087 crore (Bloomberg Estimate: Rs 1,279.4 crore)
India Geography
Comprises of formulations and consumer wellness businesses, that accounts for 37% of consolidated revenues.
Registered revenues of Rs 2212.4 crore, up 15% YoY.
Formulations business
Registered revenues increased by 12% year-on-year to Rs 1,375.8 crore.
The business accounted for 23% of consolidated revenues.
Branded formulations business grew faster than the market, with 13% year-on-year growth.
In the oncology space, the company remained the fastest-growing Indian company. The company outpaced IPM in key therapies of cardiology, gynaecology, derma, respiratory, anti-infectives and super specialty therapies of oncology and nephrology.
Share of chronic portfolio has increased consistently over the years and stood at 41.3%, which is an improvement of 430 basis points over the last three years.
Consumer Wellness business
Revenues rose 21% year-on-year to Rs 836.6 crore.
The business accounted for 14% of consolidated revenues.
The growth was broad-based and largely driven by 17% volume growth.
Personal care segment, which comprises of Nycil and EverYuthTM brands, continued to deliver robust performance with yet another quarter of strong double-digit growth.
Food and nutrition segment witnessed recovery during the quarter and posted double-digit growth.
US formulations business
Revenues rose 26% year-on-year and 23% sequentially to Rs 3,092.9 crore.
The business accounted for 51% of consolidated revenues.
Growth during the quarter was driven by new product launches and volume expansion in the base portfolio.
Launched seven new products during the quarter.
Shares of Zydus Lifesciences were trading 1.4% higher at Rs 1,298 apiece on the BSE as of 1:14 p.m., as compared with a 0.9% advance in the benchmark Sensex.
